Lupus

Otsuka Pharmaceutical’s Lupkynis (voclosporin) is the first oral treatment to be approved in Europe for the treatment of active lupus nephritis (LN) in adult patients. The drug has received approval from the European Commission (EC) in combination with mycophenolate mofetil (MMF) for the treatment of adult patients with active class III, IV or V (including […]

Domainex has revealed human ex vivo data indicating that DMXD-011 could be effective in treating interferonopathies such as lupus, Sjögren’s syndrome, and scleroderma. The drug candidate is an inhibitor of protein kinases TBK1 and IKK-epsilon, which previous studies suggest should be highly-effective in the treatment of inflammatory diseases. The efficacy of DMXD-011 has already been shown in […]